UroGen Pharma Ltd. (URGN) Comparison with companies in other sectors?

UroGen Pharma Ltd. has a share price of 46.20M. You can analyze UroGen Pharma Ltd. (URGN) competitors across different market sectors through stock heatmaps.

What are URGN's NET and operating margins?

UroGen Pharma Ltd. (URGN) operating margin is around -1.18, and net profit margin is approximately -1.51 as of the latest reports.

In what way does URGN's earnings per share (EPS) trend reflect its financial momentum?

UroGen Pharma Ltd. (URGN) EPS is -3.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for UroGen Pharma Ltd. is -6.30, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for UroGen Pharma Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for UroGen Pharma Ltd. like P/E which is -6.50, P/B which is -19.36, and PEG which is -4.29. Compare them with sector averages to evaluate if the stock is priced fairly.

UroGen Pharma Ltd.

URGN•NASDAQ

Healthcare

Biotechnology

$18.95

$0.95(5.28%)

Fundamental Analysis of UroGen Pharma Ltd. (URGN)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-3.01

P/E Ratio

-6.30

ROE

-974.87%

Net Margin

-1.51%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$875.51M

Shares OutstandingTotal number of shares issued

$46.20M

Book Value/ShareNet worth per share

$-0.98

Revenue/ShareAnnual revenue per share

$1.94

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-3.01

Net MarginNet income as percentage of revenue

-150.68%

Operating MarginOperating income as percentage of revenue

-117.51%

ROEReturn on shareholders' equity

-97486.62%

ROAReturn on total assets

-55.91%

ROCEReturn on capital employed

-52.50%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-2.26

Cash/ShareCash and equivalents per share

$4.13

FCF YieldFree cash flow as percentage of market cap

-12.32%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for URGNFinancial Ratios Analysis details for URGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for URGNSector Benchmarking details for URGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for UroGen Pharma Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of UroGen Pharma Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account UroGen Pharma Ltd.'s unique business strengths and challenges.

Key Financial Metrics for UroGen Pharma Ltd.

For UroGen Pharma Ltd., essential financial indicators include EPS -3.01, PE -6.30, and ROE -974.87. These key ratios reveal insights into UroGen Pharma Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare UroGen Pharma Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of UroGen Pharma Ltd.

Metrics like Net Margin -150.68% and ROA -55.91% shed light on how well UroGen Pharma Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether UroGen Pharma Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of UroGen Pharma Ltd.

Using ratios such as P/B Ratio -19.36 and PEG Ratio -4.29, investors can assess whether UroGen Pharma Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with UroGen Pharma Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for UroGen Pharma Ltd.

Financial health indicators, such as Debt/Equity Ratio -2.69 and Cash Flow $-2.26, provide a snapshot of UroGen Pharma Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like UroGen Pharma Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for UroGen Pharma Ltd.

Investing in UroGen Pharma Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at UroGen Pharma Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;